Pathstone Family Office’s Enovis ENOV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$662K Buy
11,556
+2,274
+24% +$133K 0.01% 897
2023
Q2
$662K Buy
9,282
+21
+0.2% +$1.2K 0.01% 632
2023
Q1
$495K Buy
+9,261
New +$537K 0.01% 701
2022
Q4
Sell
-17,511
Closed -$899K 1520
2022
Q3
$899K Buy
17,511
+8,912
+104% +$483K 0.01% 799
2022
Q2
$473K Sell
8,599
-6,234
-42% -$402K 0.01% 597
2022
Q1
$1.14M Hold
14,833
0.03% 297
2021
Q4
$1.17M Hold
14,833
0.03% 295
2021
Q3
$1.17M Buy
14,833
+618
+4% +$49.7K 0.03% 256
2021
Q2
$1.12M Buy
14,215
+3,873
+37% +$297K 0.03% 242
2021
Q1
$780K Buy
+10,342
New +$758K 0.03% 256
2019
Q2
Sell
-45
Closed -$2K 706
2019
Q1
$2K Buy
+45
New +$1.97K ﹤0.01% 756

Other funds holding ENOV

Pathstone Family Office's ENOV Position: Q3 2023 in Review

Pathstone Family Office increased its Enovis (ENOV) stake by 24% in Q3 2023, buying an estimated $133K and bringing the position to 11,556 shares worth $662K. The position accounts for 0.01% of the portfolio, ranked #897.

Pathstone Family Office first reported a position in ENOV in Q1 2019 and has held it in 11 quarters since. The position peaked at $1.17M in Q4 2021. 267 funds tracked by Wall St. Rank hold ENOV as of Q3 2023.

  • Pathstone Family Office held 11,556 shares of Enovis worth $662K as of Q3 2023.
  • Pathstone Family Office bought 2,274 Enovis shares in Q3 2023, an estimated $133K.
  • Enovis made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #897 holding.
  • Pathstone Family Office first reported a position in Enovis in Q1 2019 and has held it in 11 quarters since.
  • Pathstone Family Office's Enovis position peaked at $1.17M in Q4 2021.
  • 267 funds tracked by Wall St. Rank held Enovis as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.